Gene Expression Profiles Predict Pathologic Complete Response to Preoperative Chemotherapy with Gemcitabine, Epirubicin and Docetaxel in Primary Breast Cancer
A Schneeweiss, O Thuerigen, G Toedt, P Warnat, M Hahn, C Rudlowski, K Neben, A Benner, B Brors, R Eils, F Schuetz, D v Fournier, HP Sinn, G Bastert, C Sohn, P Lichter · Zentralblatt für Gynäkologie · 2005 · Heft 10
Bibliografische Angaben
Zusammenfassung
Aims: While primary systemic therapy (PST) has gained considerable attention, it is impossible to predict sensitivity of primary breast cancer (PBC) to specific drugs. This study was designed to discover a gene expression profile that predicts pCR to PST with gemcitabine (G), epirubicin (E) and docetaxel (Doc) administered either as triple therapy (GEDoc) or sequentially (GE→Doc) for a total of 18 weeks. Patients and Methods: Patients (pts) with PBC T2–4 N0–2 M0 underwent pretreatment core needle biopsy to collect snap frozen tissue for microarray analysis. Small amounts of isolated breast tumor RNA were amplifi…
